Departments of Medicine,1 Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 275992
Received 6 August 2001/ Accepted 20 October 2001
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Most laboratory and clinical Neisseria gonorrhoeae isolates do not express HpuAB and are unable to use Hb as the sole source of iron for growth (Hb-). A small population (ca. 0.1%) of every tested Hb- N. gonorrhoeae isolate is able to express HpuAB and utilize Hb under iron-stressed conditions (Hb+). Expression of HpuAB phase varies due to translational frameshifting resulting from slipped-strand mispairing of a poly(G) tract within the coding sequence of hpuA (8). The receptor consists of a lipoprotein, HpuA, and a transmembrane protein, HpuB. Growth on Hb is TonB dependent and requires both HpuA and HpuB (3, 8). In contrast, in the related gonococcal TonB-dependent receptors for transferrin and lactoferrin, the lipoproteins TbpB and LbpB are not absolutely required for growth, although they play a role in facilitating ligand binding (2, 4). HpuA can be isolated with HpuB by binding to Hb-agarose, but not in the absence of HpuB, indicating physical contact between these two proteins (8).
Pathogenic neisseriae can also use free heme as an iron source for growth. Growth with heme requires neither HpuAB nor TonB (3, 7, 24, 26). The existence of a heme receptor has been suggested (13, 14), but a heme receptor has never been clearly identified in either meningococci or gonococci. Pathways for entry and transport of free heme are not well understood. Construction of hemA mutants that cannot synthesize heme proved that meningococci and gonococci can utilize Hb as a heme source and that uptake of heme from either Hb or Hb-Hp requires HpuAB (17, 26). Heme-dependent growth does not require FbpA (26); FbpA is required to shuttle iron from transferrin and lactoferrin through the periplasmic space (1, 6).
As part of an effort to examine the role of HpuA and HpuB in the function of the gonococcal Hb receptor, we constructed a nonpolar hpuA deletion (
hpuA) mutant that could express HpuB under the control of the hpuA promoter. The HpuA- HpuB+ mutant was unable to grow on Hb. We were able to identify two different classes of Hb+ revertants from this HpuA- mutant. The first class had point mutations in hpuB, and their growth on Hb depended on the expression of both HpuB and TonB. The second class consisted of mutants that grew on Hb in a TonB- and HpuB-independent manner. Characteristics of the HpuA-independent/HpuB-dependent Hb utilization are reported here.
| MATERIALS AND METHODS |
|---|
|
|
|---|
|
Reagents, isotope, oligonucleotide, and DNA sequencing. All chemicals were purchased from Sigma, St. Louis, Mo., unless otherwise indicated. Iodine-125 was purchased from Amersham Pharmacia Biotech, United Kingdom. Oligonucleotides were synthesized at the Lineberger Comprehensive Cancer Center DNA Synthesis Facility of the University of North Carolina-Chapel Hill. Sequencing was carried out at the Automated DNA Sequencing Facility of the University of North Carolina-Chapel Hill with an Applied Biosystems model 373 DNA sequencer by use of the Taq Dye Terminator cycle sequencing kit (Applied Biosystems, Perkin-Elmer, Foster City, Calif.).
Construction of hpuA deletion mutants which express HpuB under the control of the hpuA promoter.
PCR-amplified DNA of the hpuA promoter region of the FA1090 Hb+ variant was inserted into the vector pCR2.1-TOPO (Invitrogen, Carlsbad, Calif.) and cloned in E. coli DH5
MCR to generate pUNCH277. The upstream PCR primer uphpuA (5'-TATCGGCCCGTCGCGCAAAACGTGTTCC-3') started at -567 bp from the beginning of the hpuA coding sequence and carried an added EagI site at the 5'end. The downstream primer hpuApro (5'-ACGCATATGATGTATTAATAATAGTTTTGATTATC-3') started at -17 bp from the ATG site and carried an added NdeI site at the 3' end.
Another plasmid, pUNCH278, carrying PCR-amplified DNA of FA1090 hpuB, including its own ribosome-binding site, was constructed in the same way. The upstream primer hpuBrbs (5'-ATACATATGGCAAAGGTTTCTTATGCCCATTCC-3') started at -13 bp from the ATG site, and the downstream primer hpu.61 (5'-TATCGGCCGGGGGCGGCGGTGCGACC-3') started at 80 bp after the TAA terminator site. They carried added NdeI and EagI sites at the 5' and 3' ends, respectively. A 1-kb cassette carrying the gene for chloramphenicol acetyltransferase (cat cassette) was inserted at the ClaI site of pUNCH278, 1,059 bp downstream from the ATG, to make pUNCH279. The hpuB::cat fragment of pUNCH279 was isolated by NdeI-AvaI double digestion and inserted into the NdeI-AvaI double-digested pUNCH277 to produce pUNCH280.
The DNA fragment from pUNCH280 carrying the hpuA promoter followed by hpuB::cat was isolated with HindIII and transformed into the FA1090 Hb+ variant to make FA7167. One of the HindIII sites was at the vector polylinker region, and the other was 687 bp before the TAA terminator site. FA7167 was Hb- and chloramphenicol resistant (Cmr). Transformation of FA7167 with pUNCH272 carrying the coding sequence for mature HpuB resulted in FA7169 (Fig. 1). The primer pair used to amplify this section of hpuB was hpu.51 (5'-TATACATATGGCAGACCCCGCGCCGCAGTC-3') and hpu.61. FA7169 was chloramphenicol sensitive (Cms) and Hb-, as expected. During the construction, we observed unexpected rare Cms Hb+ colonies on the Hb/Des plates. Two of the colonies were isolated, characterized, and named FA7168 and FA7170.
|
Mutagenesis of hmbR, tonB, and hemA.
The hmbR gene of FA7168, FA7169, and FA7170 was mutagenized with either the
or the cat cassette. The constructions started with pIRS756 (a gift from I. Stojiljkovic of Emory University) containing the hmbR gene of gonococcal strain MS11. The cat cassette was inserted at the PstI site and the
cassette was inserted at the blunted AgeI site of hmbR. The pCR2.1-TOPO-cloned hmbR::cat and hmbR::
fragments were isolated and used in transformations to derive Cmr and spectinomycin-resistant (Spr) transformants, respectively. The TonB dependence of Hb+ revertants was tested by insertional inactivation of tonB with the
cassette. This procedure used the tonB::
plasmid pUNCH173 (3) to transform various
hpuA mutants and selected for Spr. The ability of
hpuA mutants to utilize Hb as a heme source was tested by the construction of hemA mutants with the hemA::
plasmid pUNCH1306 described by Turner et al. (26).
Hb+ revertants of hpuA deletion mutants.
After initial recognition of FA7168 and FA7170, more Hb+ mutants were selected from the hmbR mutants of FA7169, FA7185 (hmbR::cat), and FA7186 (hmbR::
) by plating on Hb/Des plates.
Primers for PCR and DNA sequencing.
The design of primers was based on analysis of contiguities released from the University of Oklahoma Gonococcal Genome Sequencing Project (21). The sequence of hpuB in Hb+ mutants of
hpuA parents was examined by sequencing PCR-amplified genomic DNA. Amplification of hpuB used the primer pair hpuBrbs and hpu.61. The sequencing used eight primers as needed to read through hpuB: hpu.05 (5'-TCCCTTCAAACCCGTATTGGCT-3'), hpu.09 (5'-ATTCAGCAGCATTACCGCCG-3'), hpu.07 (5'-GCGGCGCAATACGGCTTAG-3'), hpu.11 (5'-AGATACGCCCCGCTTTCAGA-3'), hpu.10 (5'-ATTTCGACATCGCCCTCGGT-3'), hpu.08 (5'-CCGCCCAAGTGAAACACATTGT-3'), hpu.12 (5'-ATGTAGCTGACGTTGAGGCC-3'), and hpu.61.
Dependence of Hb-supported growth on HpuB expression.
DNA sequencing showed that one class of Hb+ mutants had point mutations in hpuB, which were designated hpuB*. Insertional inactivation of HpuB was carried out in
hpuA hpuB* mutants FA7186H2 and FA7186H17 to confirm that point mutation in HpuB was the factor responsible for their Hb+ phenotype. PCR products prepared from the region flanking the cat insert in the hpuB of FA7167 were used as the transforming DNA. The upstream primer, hpu.09, and the downstream primer, hpu.08, covered an hpuB fragment of 795 bp, not counting the insertion. The transformants were selected for Cmr and scored for inability to grow on Hb/Des plates.
Moving HpuB point mutants into an HpuA+ background.
The role of HpuA in gonococcal Hb utilization was examined by comparing the growth of
hpuA hpuB* and hpuA+ hpuB* mutants. PCR-amplified hpuB was prepared from two hpuB* mutants, FA7170 and FA7185H14, and moved into FA6929, which is hpuA+ hpuB::mTn3erm. Transformants were selected for growth on Hb/Des plates and scored for sensitivity to erythromycin (Ems). The hpuB of selected Hb+ Ems transformants was PCR amplified and sequenced to verify that the hpuB point mutations were preserved and the mTn3erm cassette of FA6929 had been replaced.
Plate assays for Hb and heme utilization and detergent and antibiotic sensitivity. The phenotype of various mutants was assessed by spreading 100 µl of a 1:100 dilution of cell suspensions at an OD600 of 0.4 onto GCB/Des or GCB plates. To test for growth, wells (0.6 cm in diameter) were cut into the agar and filled with 60 µl of heme at 0.1 mg/ml or Hb at 10 mg/ml (26). To test for antimicrobial sensitivity, filter paper disks (0.6 cm in diameter) were placed on the GCB plate surface and 5 µl of test solution was dropped at the center of the disks. Chloramphenicol was used at 0.3 µg/µl, rifampin was used at 0.1 µg/µl, and Triton X-100 was used at a 1:100 dilution.
Liquid culture assays. Liquid cultures were started from gonococci grown overnight on Chelex-treated defined medium (CDM) plates containing 5 µM ferric nitrate (12). Ten milliliters of liquid CDM was inoculated to approximately 20 Klett units and incubated with shaking at 37°C in a 5% CO2 atmosphere for 2 h. Once the starting culture reached about 30 Klett units, fresh CDM containing the iron sources of interest was inoculated to a starting Klett unit of about 5 for Hb cultures and about 10 for heme cultures. Hb was used at a final concentration of 1 µM, while heme was tested at concentrations varying between 0.05 and 5 µM. Desferal was added to all Hb and heme media to 100 µM. For iron-stressed growth, only Desferal was added to the liquid culture. Human serum albumin (HSA) was added as indicated to a final concentration of 16 µM.
Hb-binding assays. Two kinds of Hb-binding assays were carried out using either biotinylated human Hb or iodinated anti-Hb antibody. The biotinylated Hb-whole-cell dot blot assay has been described previously (7). The radioimmunoassay used iodinated goat anti-human Hb antibodies (affinity purified; Bethyl Laboratories, Montgomery, Tex.) instead of Hb because of the difficulty in maintaining the stability of iodinated Hb. Iodination was done in IODO-GEN-coated iodination tubes from Pierce (Pierce Endogen, Rockford, Ill.) and followed the suggested protocol. The assay used MultiScreen plates purchased from Millipore (Bedford, Mass.). CDM solution was the suspension and washing buffer, and 0.5% dry milk was used as the blocker.
The wild type and the
hpuA strains to be tested were grown in iron-replete and iron-stressed cultures and prepared as OD600 = 0.2 cell suspensions in CDM solution. Hb was added to the final concentration of 0.1 µM to 100 µl of gonococcal suspensions in the wells. The mixture was incubated at room temperature for 30 min and filtered through the MultiScreen plate. After three washes with CDM solution, labeled goat anti-human Hb antibody was added to approximately 106 cpm per well. After another incubation of 30 min, the wells were washed three times again, disks at the bottom of wells were punched out, and radioactivity was counted in a gamma scintillation counter. Specific Hb binding values were derived from the difference between the cpm bound in wells with iron-stressed gonococci and those bound in wells with iron-replete gonococci. Specific counts accumulated from each test strain were then compared with corresponding counts from the wild-type strain using paired Students t test.
| RESULTS |
|---|
|
|
|---|
hpuA hpuB+ mutant of FA1090, FA7169, as illustrated in Fig. 1. Moving the
hpuA hpuB::cat DNA fragment from pUNCH280 into the Hb+ variant of FA1090 resulted in Cmr Hb- FA7167. Transformation of FA7167 with pUNCH272, which contained the wild-type hpuB sequence, removed the cat cassette insert and resulted in FA7169. The hpuB sequence of FA7169 was identical to that of FA1090. The hpuB gene, along with its ribosome-binding site, followed the hpuA promoter at a distance equal to that between hpuA and the promoter in FA1090, and HpuB was expressed under iron-stressed growth conditions. FA7169 could not grow on Hb as a sole iron source but expressed HpuB, as previously reported for the analogous hpuA nonpolar insertion mutant FA6983 (8).
During the construction of FA7169, two mutants, FA7168 and FA7170, were discovered which were phenotypically Cms but grew on Hb/Des plates (Hb+). DNA sequencing revealed that both mutants had the expected deletion of hpuA. FA7168 was
hpuA hpuB::cat, while FA7170 was
hpuA hpuB*650 (G217D), with a point mutation 650 bp downstream from the beginning of the coding sequence. Both FA7168 and FA7170 grew on Hb/Des after insertional mutagenesis of hmbR (data not shown), and thus HmbR was not responsible for the Hb+ phenotype of either mutant. Insertional inactivation of tonB resulted in an Hb- phenotype in FA7170, but a tonB mutant of FA7168 was still Hb+ (data not shown), indicating that they used different mechanisms for Hb-supported growth. FA7168 was unable to grow on plates containing chloramphenicol (1 µg/ml) and was highly sensitive to rifampin and Triton X-100, while FA1090, FA7167, FA7169, and FA7170 were able to grow on the same plates (data not shown).
After these initial characterizations, additional Hb+ mutants were selected from hmbR mutants of FA7169, FA7185 (hmbR::cat) and FA7186 (hmbR::
), on Hb/Des plates at frequencies of about 10-6. DNA sequencing confirmed that there were two classes of Hb+ revertants. One had single point mutations in hpuB, and these were designated
hpuA hpuB* mutants. The other class did not have mutations in hpuB, but, like FA7168, all were highly sensitive to Triton X-100 and rifampin (data not shown). Mutants of this class were designated
hpuA hgbX mutants, pending identification of the gene(s) involved in the Hb+ phenotype. All 15 hpuB* mutants contained a single predicted amino acid alteration, which were clustered toward the C-terminal end of HpuB. Three mutations were isolated independently multiple times (Fig. 2).
|
hpuA hpuB+ FA7169 and the Hb+
hpuA hpuB* mutants expressed HpuB under iron-stressed conditions (Fig. 3). Insertional inactivation of the altered HpuB in FA7186H2 and FA7186H17 resulted in Hb- transformants FA7246 and FA7247 (data not shown). Thus, expression of HpuB was required for the utilization of Hb for growth. Further proof that the point mutations in hpuB caused the Hb+ phenotype was obtained by transforming FA7169 with PCR-amplified hpuB DNA from FA7170 or FA7185H14. The hpuB gene was sequenced from two Hb+ transformants of each transformation and confirmed that each carried the same hpuB point mutation as the donor (data not shown).
|
hpuA hpuB* mutants than FA1090 Hb+ (Fig. 4), suggesting that the hpuB* mutants required a higher Hb concentration for growth than the wild type. Free heme also could be used by the hpuB* mutants as an iron source, as previously described for FA1090 Hb+ (26). Both Hb+ FA1090 and Hb- FA7169 showed similar heme growth phenotypes, with an inner zone of inhibition and an outer zone of growth around the well (Fig. 4). The zone of inhibition reflects the sensitivity of these strains to heme; they only grew on a narrow range of heme concentrations.
|
hpuA hpuB* mutants in liquid culture containing 1 µM Hb and 100 µM Desferal was inhibited by HSA, while that of FA1090 Hb+ was not inhibited by HSA (Fig. 5). Thus, growth of these mutants apparently relied on free heme released extracellularly from Hb. The role of HpuA was further investigated by constructing hpuA+ derivatives of the hpuB* strains FA7170 and FA7185H14 (FA7242 and FA7243, respectively). Growth of the hpuA+ hpuB* strains on Hb was not inhibited by HSA (Fig. 5), confirming the importance of HpuA in allowing the use of heme from Hb.
|
-aminolevulinic acid to grow on GCB plates, but were able to grow on heme/Des (data not shown). Both FA7244 and FA7245 were able to grow on Hg/Des plates, but FA7288 did not grow on the same plate (data not shown). These results demonstrated that Hb was used as a heme source by the
hpuA hpuB* mutants, while
hpuA hpuB+ FA7169 could not use Hb as a heme source. The uptake of free heme by hpuB* mutants was studied by measuring heme-dependent growth in liquid cultures. At heme concentrations of 1 and 5 µM, growth of all hpuB* and hpuB+ strains was indistinguishable and quickly reached a plateau. At heme concentrations of 0.05 to 0.1 µM, all strains grew poorly (data not shown). At 0.5 µM heme, strains expressing HpuB grew better than the HpuB- FA7167. The hpuB* mutants FA7170 and FA7186H16 grew slightly but reproducibly better than their hpuB+ parents, FA7169 and FA7186 (Fig. 6 and data not shown). Thus, at limiting heme concentrations, hpuB* mutants apparently transported more free heme than their hpuB+ parents.
|
hpuA hpuB* mutants bound Hb, although apparently less than FA1090 Hb+. The binding corresponded to the expression of HpuB, as detected by anti-HpuB antibodies (data not shown). Radioimmunoassays further confirmed that Hb bound to all mutants that expressed HpuB regardless of their growth phenotype. FA7169, which was Hb-, made HpuB and bound Hb, whereas FA7168, which was Hb+ but could not express HpuB, did not bind Hb (data not shown). Hb binding to each
hpuA mutant, hpuB+ or hpuB*, was significantly less than that of the wild type (P < 0.01, paired Students t test). With the exception of FA7185H14, all
hpuA mutants bound less than 30% of the Hb bound to the wild type. Hb binding generally was not increased by the hpuB* mutations; FA7185H14 was the only strain that bound significantly more Hb than its hpuB+ parent (Fig. 7).
|
| DISCUSSION |
|---|
|
|
|---|
hpuA mutant at frequencies of about 10-6. Two classes of revertants were identified: hpuB* mutants, which had single point mutations in hpuB, and hgbX mutants, which had mutations in a still unidentified locus or loci. Involvement of HmbR, the single-component, TonB-dependent outer membrane receptor known to bind and acquire iron from Hb in meningococci (22), was ruled out after insertional mutagenesis of hmbR. The neisserial transferrin and lactoferrin receptors are similar to the HpuAB Hb receptor. All are bipartite, TonB-dependent outer membrane receptors, consisting of a lipoprotein and an integral outer membrane protein. The lipoproteins TbpB and LbpB are necessary for full binding of ligand, but are not absolutely required for iron acquisition (2, 4, 10, 19). In contrast, both HpuA and HpuB are required for iron acquisition from Hb in N. gonorrhoeae (8) and Neisseria meningitidis (18). However, the current work proves that the requirement for HpuA can be bypassed under certain circumstances by point mutations in HpuB.
Growth on Hb by
hpuA hpuB* mutants was TonB and HpuB dependent, indicating that iron acquisition was an energy-dependent process involving HpuB. All
hpuA mutants bound less Hb than the wild type, confirming the importance of HpuA in the ligand binding. The point mutations in HpuB that restored growth on Hb in the absence of HpuA did not significantly increase Hb binding, with the exception of FA7185H14. None of the mutations in HpuB restored full Hb binding to the cell surface, and therefore growth apparently was not due merely to increased ligand binding. The low Hb binding efficiency of
hpuA hpuB* mutants might have contributed to the higher Hb concentration required for growth on Hb.
HSA inhibited Hb-dependent growth of hpuB* mutants, suggesting that free heme was released external to the outer membrane before it was internalized, presumably by passing through a pore in the integral outer membrane protein HpuB. Proof that heme released from Hb entered intact was provided by demonstration of Hb-dependent growth in
hpuA hpuB* hemA::
mutants. In these mutants, heme released from Hb was used both as a porphyrin source and as an iron source. The mechanism of heme removal from Hb is currently unknown.
Growth of
hpuA hpuB* mutants on Hb was inhibited by HSA, but HSA was not growth inhibitory in hpuB* strains that expressed HpuA. These results suggested that HpuA both increased Hb binding and allowed use of heme released externally from Hb. The current results are insufficient to determine precise roles of HpuA or HpuB in ligand binding. HpuA might increase Hb binding by stabilizing a conformation of HpuB that has high affinity for Hb. Apparent protection of heme from HSA binding by HpuA could have been due to steric effects of the Hb receptor, but also could have been due to increased release of heme from HSA.
In liquid cultures with limiting heme concentrations,
hpuA hpuB* mutants grew slightly better than their
hpuA hpuB+ parents did. Thus, the point mutations in HpuB might have altered the transmembrane barrel and increased the ability of free heme to traverse the membrane. However, we were unable to determine the relative contribution of heme binding and heme entry to the heme-dependent growth of
hpuA hpuB* mutants. With regard to Hb-dependent growth, our data did not show a general increase of Hb binding in the hpuB* mutants in comparison to their hpuB+ parents. The hpuB* mutations could have effected either increased heme release from Hb or increased transport of heme through HpuB or both.
The mutations in HpuB occurred in clusters, particularly near the C terminus, but the meaning of this distribution is not yet clear. None of the mutations was likely to be in the putative N-terminal plug that is characteristic of TonB-dependent siderophore receptors (5). Until a crystal structure is determined for HpuB, the exact location of point mutations in the barrel or outer loops of HpuB will remain conjectural. The point mutations in HpuB that restored function of the receptor in the absence of the otherwise requisite partner HpuA should prove helpful in ultimately understanding the structure-function relationship in HpuAB. Likewise, the other class of mutations, designated hgbX, should prove useful in understanding Hb receptor-independent and TonB-independent mechanisms for heme utilization, and these studies are being actively pursued.
| ACKNOWLEDGMENTS |
|---|
This work was supported by NIH grants AI26837 and AI31496 to P. Frederick Sparling.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Appl. Environ. Microbiol. | Infect. Immun. | Eukaryot. Cell |
|---|---|---|
| Mol. Cell. Biol. | J. Virol. | Microbiol. Mol. Biol. Rev. |
| ALL ASM JOURNALS |